PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Conjugate vaccines and others - Market size and forecast 2018-2023 • Live-attenuated vaccines - Market size and forecast 2018-2023 • Toxoid vaccines - Market size and forecast 2018-2023 • Inactivated vaccines - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • Monovalent vaccines • Multivalent vaccines PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • CSL Limited • GlaxoSmithKline plc • Merck & Co., Inc. • Pfizer Inc. • Sanofi PART 15: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Global vaccine market Exhibit 02: Segments of global vaccine market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pediatric vaccines in the pipeline Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Conjugate vaccines and others - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Conjugate vaccines and others - Year-over-year growth 2019-2023 (%) Exhibit 22: Sales of leading conjugate vaccines 2015-2017 ($ millions) Exhibit 23: Live-attenuated vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Live-attenuated vaccines - Year-over-year growth 2019-2023 (%) Exhibit 25: Sales of leading live-attenuated vaccines 2015-2017 ($ millions) Exhibit 26: Toxoid vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Toxoid vaccines - Year-over-year growth 2019-2023 (%) Exhibit 28: Inactivated vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 29: Inactivated vaccines - Year-over-year growth 2019-2023 (%) Exhibit 30: Market opportunity by product Exhibit 31: Customer landscape Exhibit 32: Market share by geography 2018-2023 (%) Exhibit 33: Geographic comparison Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 35: North America - Year-over-year growth 2019-2023 (%) Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Incidence rates for malaria 2017 (reported by the World Bank) Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Immunization programs for children Exhibit 46: Recently approved vaccines by the FDA Exhibit 47: Impact of drivers and challenges Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: CSL Limited - Vendor overview Exhibit 54: CSL Limited - Business segments Exhibit 55: CSL Limited - Organizational developments Exhibit 56: CSL Limited - Geographic focus Exhibit 57: CSL Limited - Segment focus Exhibit 58: CSL Limited - Key offerings Exhibit 59: GlaxoSmithKline plc - Vendor overview Exhibit 60: GlaxoSmithKline plc - Business segments Exhibit 61: GlaxoSmithKline plc - Organizational developments Exhibit 62: GlaxoSmithKline plc - Geographic focus Exhibit 63: GlaxoSmithKline plc - Segment focus Exhibit 64: GlaxoSmithKline plc - Key offerings Exhibit 65: Merck & Co., Inc. - Vendor overview Exhibit 66: Merck & Co., Inc. - Business segments Exhibit 67: Merck & Co., Inc. - Organizational developments Exhibit 68: Merck & Co., Inc. - Geographic focus Exhibit 69: Merck & Co., Inc. - Segment focus Exhibit 70: Merck & Co., Inc. - Key offerings Exhibit 71: Pfizer Inc. - Vendor overview Exhibit 72: Pfizer Inc. - Business segments Exhibit 73: Pfizer Inc. - Organizational developments Exhibit 74: Pfizer Inc. - Geographic focus Exhibit 75: Pfizer Inc. - Segment focus Exhibit 76: Pfizer Inc. - Key offerings Exhibit 77: Sanofi - Vendor overview Exhibit 78: Sanofi - Business segments Exhibit 79: Sanofi - Organizational developments Exhibit 80: Sanofi - Geographic focus Exhibit 81: Sanofi - Segment focus Exhibit 82: Sanofi - Key offerings Exhibit 83: Validation techniques employed for market sizing  

CSL Limited GlaxoSmithKline plc Merck & Co. Inc. Pfizer Inc. and Sanofi